During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
Researchers from the Broad Institute and NIH characterized a CRISPR-associated transposase that can integrate DNA into unique sites in the E. coli genome.
ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.
An analysis using UK Biobank data indicates that the CCR5-Δ32 gene mutations He Jiankui reportedly attempted to introduce into human embryos may be deleterious.
Using CRISPR mouse and iPS cell models, the researchers showed that a rare maternally inherited variant is a genetic modifier of two paternally inherited variants.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
Silence Therapeutics aims to use the database to help identify new drug targets, as well as for patient recruitment and stratification in clinical trials.
The commission will develop a framework for scientists, clinicians, and regulatory authorities on the appropriate use of human germline genome editing.
To solve the problem, the researchers developed new variants of the editors that still edit DNA efficiently but have significantly lower RNA editing activity.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
Researchers found that both CBEs and ABEs can cause transcriptome-wide RNA edits, which has implications for the research and therapeutic uses of base editors.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
